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Sustained systemic arterial hypertension induced by extended
hypobaric hypoxia
NOSTRATOLA D. VAzIRI and ZONG QIAN WANG
Division of Nephrology, Department of Medicine, University of California, Irvine, Irvine, California, USA
Sustained systemic arterial hypertension induced by extended hypo-
baric hypoxia. Regular administration of recombinant erythropoietin
(EPO) is frequently complicated by a rise in arterial blood pressure. We
therefore asked if prolonged stimulation of endogenous EPO production
has the same effect. To this end, male Sprague-Dawley rats were placed in
a hypobaric chamber (390 mm Hg) for 24 days. The control (NL) group
was placed in the chamber at normobaric condition. The animals were
then removed from the chamber and monitored through day 108. Plasma
EPO peaked within 24 hours and returned to baseline by day 7 and
remained so thereafter. Hematocrit rose steadily during the hypoxic phase
and declined steadily during the normobaric phase, reaching the baseline
on day 45. This was accompanied by parallel changes in erythrocyte mass
and blood volume. The rise in hematocrit during hypoxia was accompa-
nied by a parallel rise in blood pressure which peaked on day 24. Despite
the restoration of normal hematocrit, erythrocyte mass and blood volume
following resumption of normoxia, blood pressure remained elevated
throughout the observation period. To dissect the role of hypoxia from
that of the associated rise in hematocrit, the experiments were repeated
using a group of rats whose hematocrits were kept constant by repeated
phiebotomies. These animals exhibited a sustained rise in blood pressure
identical to that found in the original group. Thus, prolonged hypobaric
hypoxia leads to a severe hematocrit-independent systemic hypertension
(HTN) that persists long after the restoration of normoxia. Given the
transient nature of the rise in its plasma concentration, endogenous EPO
does not appear to play a role in the genesis of the observed systemic
HTN. The authors believe that this animal model can be used for future
studies of the mechanism, consequences and treatment of acquired HTN.
Regular administration of recombinant human eiythropoietin
(EPO) in patients with chronic renal failure (CRF) is frequently
complicated by development of de novo HTN or exacerbation of
pre-existing HTN [1—10]. The EPO-associated rise in arterial
blood pressure usually manifests within a few weeks to months
after initiation of therapy and generally subsides with its discon-
tinuation [1—10]. The precise mechanism(s) by which EPO raises
arterial blood pressure is uncertain. Increased hematocrit and a
direct or indirect effect of EPO on vascular smooth muscle tone
have been proposed as possible candidates [9—12].
Given the fact that regular administration of exogenous EPO
can raise systemic arterial blood pressure, we hypothesized that
chronic stimulation of endogenous EPO may have a similar effect.
To test this hypothesis we studied rats during and after a 24-day
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exposure to hypobaric hypoxia. The data were compared with
those obtained from a group of sham-treated rats kept in a similar
environment under normobaric condition. The results showed
that after an early peak, plasma EPO returned to baseline within
a few days despite persistent hypoxia. However, arterial blood
pressure began to rise steadily after restoration of normal plasma
EPO level reaching a peak by the end of the hypoxic period and
remained elevated thereafter despite restoration of normoxic
condition. These observations disproved the direct role of endog-
enous EPO as a culprit in the pathogenesis of the observed
hypoxia-induced sustained systemic HTN. However, the experi-
ments led to identification of a model of acquired HTN that may
be useful in future studies of the pathogenesis, complications and
management of HTN.
Methods
Animals
Male Sprague-Dawley rats (Charles River, Wilmington, MA,
USA) weighing 270 to 300 g were used in these experiments. They
were allowed free access to food (regular rat chow, Purina Mills
Inc., Brentwood, MO, USA) and water throughout the study
period. The animals were randomly assigned to the hypoxic
(group A) and sham-treated control groups. Animals assigned to
the hypoxic group were placed in a hypobaric chamber in which
the air pressure was kept at 390 mm Hg using a continuous
vacuum pump and an adjustable inflow valve. The interior of the
chamber was maintained at the ambient temperature. A normal
interior light cycle was accommodated through glass windows in
the chamber's structure.
The hypoxic group was kept under hypobaric conditions for 24
days. The chamber was briefly opened thrice weekly for routine
animal care, measurement of arterial blood pressure and procure-
ment of blood samples, as appropriate. Animals randomized to
the sham-treated control group were treated in an identical
manner excepting normal air pressure within the chamber. After
the conclusion of the 24-day exposure to hypobaric hypoxia or
sham-treatment, the rats were placed in regular cages and fol-
lowed through day 108. In an attempt to dissect the possible role
of hypoxia from that of the associated rise in hematocrit and
erythrocyte mass on arterial blood pressure, the experiments were
repeated using regular phlebotomies gauged to keep the hemat-
ocrit constant (group B). This was accomplished by orbital sinus
puncture (under light anesthesia) for measurement of hematocrit
and blood removal as needed two to three times weekly.
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Arterial blood pressure was measured using a tail sphygmoma-
nometer (Harvard Apparatus, South Natick, MA, USA) at base-
line (day 0) and on days 1, 3, 7, 14, 24, 25, 31, 45, 66 and 108.
Blood samples were obtained by orbital sinus puncture under light
anesthesia at appropriate intervals. Hematocrit, platelet count
and serum creatinine were measured using standard laboratory
techniques.
Plasma erythropoietin was measured by radioimmunoassay as
previously described [13] using a kit purchased from Incstar Corp.
(Stillwater, MN, USA).
Measurement of blood volume
Blood volume was measured on days 24 and 66 as follows. After
insertion of arterial and venous catheters, the animals were
injected with 0.1 ml of a radioiodinated (1251) serum albumin
preparation (RISA, 0.75 jxCi/rat) through the venous catheter.
The venous catheter was then flushed with 0.1 ml normal saline,
and blood samples (0.3 ml) were obtained from the arterial line at
5, 10 and 20 minutes for determination of hematocrit and plasma
radioactivity. Plasma radioactivity was determined in 0.1 ml of
plasma obtained at the above internals and plotted against time
using semilogarithmic paper. The plasma radioactivity at time
zero was determined by extrapolation using the above curve. On
each occasion, the radioactivity present in 0.1 ml of the RISA
preparation was separately measured. Measurements were car-
ried out for one minute using a gamma counter (Gamma 5500B,
Beckman Inc., Irvine, CA, USA). Residual radioactivity remain-
ing in the venous catheter was determined at the end of each
experiment. The unbound 125! was determined after precipitation
of the plasma proteins by 10% trichloroacetic acid. The amount of
albumin-bound radioactivity delivered was calculated using the
following equation:
Albumin-bound radioactivity delivered = (CPM/ml of RISA X
volume RISA injected) — CPMvenous catheter — CPM unbound 125j
Plasma volume was calculated by dividing the above value by the
plasma radioactivity concentration (CPM/ml) at time zero. Blood
volume was derived from the equation:
Blood volume = Plasma volume/(1 — hematocrit)
Erythrocyte mass was calculated from blood volume and hema-
tocrit.
Endothelin determination
Plasma endothelin was measured by radioimmunoassay (RIA)
using reagents obtained from Nichols Institute Diagnostics (San
Juan Capistrano, CA, USA). EDTA plasma samples were ex-
tracted with acetone, and the acetone extract was dried under
nitrogen (extraction efficiency was 90%). The dried extract was
reconstituted and assayed in an RIA using '251-endothelin and
rabbit anti-endothelin. The bound/free separation was achieved
using second antibody separation procedure (donkey anti-rabbit
gamma globulin). To avoid interassay variations, all samples were
assayed in a single session. The intra-assay variation for this test
was less than 8%. Sensitivity of the assay was I pg/mI for a 1 ml
sample size. The specificity of the antibody was as follows:
endothelin 1 to 100%, endothelin 2 to 52% and endothelin 3 to
96%. The assay had minimal cross reactivity with big endothelin
(7%) and no cross reactivity with ANP, AVP, angiotensin II or
ACTH.
Arginine vasopressin (A VP) determination
Plasma AVP was measured by RIA following bentonite extrac-
tion as described by Skowsky, Rosenbloom and Fisher [14]. In a
typical assay, 1 ml of plasma was extracted with bentonite (3 mg),
and the AVP bound to the bentonite was eluted using acidified
acetone. The eluate was dried under nitrogen. The AVP-contain-
ing residue was reconstituted and assayed by RIA. In the RIA, an
aliquot of the reconstituted material was mixed with rabbit
anti-AVP and incubated for 72 hours at 4°C. [1251] AVP was
added, and the incubation was continued for another 24 hours.
Bound/free separation was achieved using a second antibody
(goat antirabbit gamma globulin). Extraction efficiency was mon-
itored routinely, and the final results were corrected for extrac-
tion efficiency (70%). The sensitivity of the assay is 1 pg/mI. All
samples were assayed in a single session. The intra-assay variation
of the assay is 9%.
Atrial natriuretic peptide (ANP) determination
Plasma samples were extracted using Sep-Pak column as de-
scribed by Yandle et a! [15]. The antibody used in the assay
recognizes the amino-terminal end of the ANP molecule [16]. In
a typical assay 1 ml of plasma was acidified with 0.1 ml of 1 N HCI,
and the mixture was loaded onto a C18 Sep-Pak column. The ANP
bound to the column was eluted with 80% methanol in trietha-
nolamine buffer (vol/vol), pH 4.0. The eluate was then dried under
nitrogen and the residue reconstituted in RIA buffer (pH 7,1,
containing 0.01 M sodium phosphate, 0.85% sodium chloride,
0.05 M EDTA and 0.05% bovine serum albumin). The ANP-
containing solution was mixed with rabbit anti-ANP and incu-
bated for 24 hours at 4°C. [1251] ANP was added and the
incubation was continued for an additional 48 hours. At the end of
the incubation, a second antibody (goat antirabbit gamma globu-
lin) was added to separate the free from bound. The extraction
efficiency of the assay was 75%. The intra-assay variation of this
test is 8.4%, and the assay is sensitive to 10 pg/mI. All samples
were assayed in a single session.
Statistical analyses
Data are presented as mean SEM. Multiple measure analysis
of variance (ANOVA), Duncan's multiple range test and regres-
sion analysis were used in evaluation of the data. P values equal to
or less than 0.05 were considered significant.
Results
Plasma EPO
Data are depicted in Figure 1. Plasma concentration of EPO in
group A animals climbed to a peak 24 hours after exposure to
hypobaric conditions. Thereafter, EPO concentration declined
sharply returning to the baseline values on day 7 despite persistent
exposure to hypoxia through day 24. There was a slight and
transient fall in EPO level below the baseline values shortly after
restoration of normobaric conditions.
Hematocrit
Data are depicted in Figures 2 and 3. Group A animals
exhibited a steady rise in hematocrit during the 24 day period of
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exposure to hypobaric conditions. The increase in hematocrit
attained statistical significance on day 7 and reached a peak on
day 24. This was followed by a steady decline in hematocrit during
the normobaric phase of the study, reaching the baseline values on
Data are shown in Figure 4. Blood volume measurement
obtained at the end of the 24-day hypoxic phase in group A
animals was significantly greater than that of the sham-treated
counterpart. However, repeat measurements obtained on day 66
revealed equal values in the two groups. The observed rise in the
blood volume in group A animals after 24-day exposure to hypoxia
was exclusively due to the expansion of erythrocyte mass. In fact,
plasma volume remained virtually unchanged during the observa-
tion period in the study groups.
Blood pressure
Data are illustrated in Figures 2 and 3. Arterial blood pressure
remained steady through day 3 of hypobaric hypoxia. It began to
progressively rise thereafter reaching a peak on day 24 of hypo-
baric experience. The rise in arterial blood pressure during the
hypoxic phase of the study closely paralleled the rise in hematocrit
in group A animals. A significant correlation was found between
changes in arterial blood pressure and hematocrit (r = 0.81, P <
0.005) during this period in group A (Fig. 5). Contrary to our
expectation, blood pressure remained elevated throughout the
study period despite restoration of normoxia beyond day 24 and
subsequent normalization of hematocrit and blood volume. No
significant change was observed in arterial blood pressure in the
sham-treated group during the observation period. Interestingly,
the hypoxic animals subjected to regular phiebotomies (group B)
exhibited a severe sustained systemic HTN identical to that found
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Fig. 1. Plasma eiythropoietin concentration at baseline (time 0) and during
the hypoxic (days 1 to 24) and post-hypoxic (days 25 to 108) periods. Data
are given as mean SaM, N = 9. *p < 0.001 relative to baseline value
(ANOVA and Duncan's multiple range test).
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Fig. 2. Changes of (A) arterial blood pressure and (B) hematocrit at baseline
(day 0) and during the hypoxic (days I to 24) and post-hypoxic (days 25 to
108) periods. Data given as mean SEM, N = 10 in each group. Symbols
are: (—•—) hypoxia; (--A--) control; *p < 0.001 versus baseline value
(ANOVA and Duncan's multiple range test).
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Fig. 3. Hematocrit and arterial blood pressure in the hypoxic group subjected
to regular phlebotomies to keep hematocrit from rising. Data are given as
mean SEM (N = 10) for the baseline (day 0), hypoxic (days ito 24) and
post-hypoxic (days 25 to 108) periods. p < 0.001 versus baseline value
(ANOVA and Duncan's multiple range test).
day 45. As expected, the hematocrit remained virtually constant in
the sham-treated control animals. Likewise, by design, hematocrit
remained unchanged in the hypoxic group B animals that were
subjected to regular phlebotomies.
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Fig. 4. (A) Blood volume, (B) plasma volume and (C) blood cell volume at
the end of the 24-day hypoxic period (day 24) and several weeks after
restoration of normobaric condition (day 66). Data are compared with those
obtained in the sham-treated controls. Data are given as mean SCM, N =
5 in each group. Symbols are: (0) control; (W) hypoxic; *p < 0.01 versus
controls.
in their group A counterparts despite lack of increased hemato-
crit. These observations clearly suggest that the systemic HTN
observed with prolonged hypoxia is not due to the associated rise
in hematocrit.
Plasma vasoactive hormones
Plasma endothelin concentration rose significantly reaching a
peak on day 2. This was followed by a gradual decline toward the
baseline values by the end of the hypoxic period. Subsequent
measurements obtained during the post-hypoxic period were not
significantly different from the pre-hypoxic baseline values (Fig.
6).
Exposure to hypoxia resulted in a steady rise in plasma ANP
concentration reaching a peak by day 7. Thereafter, plasma ANP
level gradually declined to a new plateau which was significantly
above baseline level (Fig. 7).
Plasma AVP rose insignificantly early in the course of hypoxia.
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Fig. 5. Correlation between hematocrit and arterial blood pressure using
values obtained at baseline and during the 24-day exposure to hypoxia (r =
0.81, P < 0.005, N = 10).
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Fig. 6. Plasma endothelin concentration prior to (day 0), during (days I to
24), and after (days 25 to 108) exposure to hypobaric hypoxia. Data are given
as mean SCM, N = 10. P < 0.001, < 0.05 versus baseline value.
Thereafter, the AVP level returned to baseline where it remained
throughout the course of the observation period (Fig. 8).
Discussion
Animals maintained under hypoxic condition exhibited a
marked but transient rise in plasma erythropoietin concentration,
reaching its peak within 24 hours. This was followed by a gradual
rise in hematocrit beginning on day 3, and reaching a peak at the
conclusion of the hypoxic phase on day 24. The gradual rise in
hematocrit was accompanied by a sharp fall in plasma EPO to the
baseline level by day 7. Thus, the increase in the oxygen carrying
capacity occasioned by the rise in erythrocyte mass must have
served to offset the effect of reduced oxygen tension on EPO
production. Accordingly, plasma EPO concentration returned to
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and remained at baseline level for the remainder of the hypoxic
phase in the face of rising hematocrit.
The rise in hematocrit was associated with a marked rise in
blood volume along with a parallel and simultaneous rise in blood
pressure during the hypoxic phase reaching a peak on day 24.As
expected, following the restoration of normal oxygen tension
beyond day 24, hematocrit declined steadily returning to the
baseline value by day 45. Interestingly, despite the decline in the
hematocrit and blood volume to baseline, blood pressure re-
mained severely elevated throughout the remainder of the 108-
day observation period.
The parallel rises in hematocrit and arterial blood pressure
during the hypoxic phase suggested a possible causal relationship
between the two processes. This was thought to be due to the
hypoxia-induced increase in erythrocyte mass, expansion of blood
volume and the rise in erythrocyte concentration leading to
increased blood viscosity and hence total vascular resistance.
Thus, the associated changes in both components of blood
pressure; that is, circulating volume and vascular resistance were
thought to support the observed rise of blood pressure in the
presence of an, otherwise, intact cardiovascular system, In an
attempt to test the validity of this construct, we sought to dissect
the possible role of hypoxia from that of the associated expansion
of eiythrocyte mass and concentration. To this end we repeated
the experiments in a group of animals that were subjected to
hypobaric condition as in group A, but whose hematocrit was kept
constant by regular phlebotomies gauged to keep hematocrit from
rising. To our surprise these animals exhibited a blood pressure
rise which was virtually identical in pattern and magnitude to that
seen in the original group. This observation clearly demonstrated
that the observed HTN was mediated by a hematocrit-indepen-
dent mechanism. In an attempt to exclude the possible effect of
recurrent stress associated with phiebotomies, we have repeated
these experiments in animals with dietary iron deficiency and have
found identical results (data not shown).
The possible direct contribution, if any, of the endogenous
EPO, per se, to the pathogenesis of the observed systemic HTN is
tenuous. First, the rise in plasma EPO was confined to the early
phase of the hypoxic period preceding the onset of systemic HTN.
In fact, the EPO levels were at or below the basal levels during the
remainder of hypoxic and post-hypoxic periods when systemic
HTN was fully expressed. Moreover, exogenous EPO-induced
HTN is readily reversed with discontinuation of therapy. In
contrast, HTN persisted indefinitely after the transient rise in
endogenous EPO production in animals employed here. These
observations tend to strongly argue against the direct role of
endogenous EPO in the pathogenesis of the sustained systemic
HTN in the study animals. Likewise, the observations made in the
phlebotomized group tend to exclude the indirect role of EPO
through its erythropoietic action.
Based on the above observation, neither endogenous EPO nor
the rise in hematocrit seemed to play a central role in the pathogen-
esis of the observed hypoxia-induced systemic HTN. We thus
sought to examine the changes of several vasoactive hormones in
the course of the study period to search for the possible mecha-
nism(s).
Rats exposed to hypobaric hypoxia showed a threefold increase
in plasma endothelin level by day 2. While values began to decline
thereafter, they did not reach the baseline concentrations until
the end of the hypoxic period on day 24. Interestingly, however,
the onset of HTN on day 7 did not correspond with the peak
endothelin level which occurred on day 2. Thus, the role of
hypoxia-induced elevation of endothelin in the genesis of the
associated systemic HTN is unclear. The rise in plasma endothelin
observed in rats exposed to hypobaric hypoxia is consistent with a
twofold rise in plasma endothelin reported in a group of normal
volunteers upon ascent from 490 m to a high altitude of 4559 m
corresponding with the onset of acute pulmonary HTN [17].
Likewise, chronic hypoxia has been shown to increase pulmonary
tissue endothelin-1 and ET-A and ET-B receptor gene expres-
sions [181. In addition, ET-A receptor antagonist has been shown
to abrogate acute hypoxia-induced pulmonary HTN in rats [19].
These observations suggest that local induction of endothelin by
hypoxia in the lungs may mediate the associated pulmonary HTN.
The available data do not allow a definitive conclusion as to the
role of endothelin in the genesis of hypoxia-induced sustained
systemic HTN observed in the present study. Further studies
employing ET-A receptor antagonist are planned to address this
issue in the present model.
Animals exposed to hypoxia showed a more than fourfold rise
in plasma ANP concentration by day 7. Although the ANP level
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Fig. 7. Atrial natriuretic peptide (ANP) prior to (day 0), during (days I to
24), and after (days 25 to 108) exposure to hypobaric hypoxia. Data are given
as mean SEM, N = 10. *P < **p < 0.05 versus baseline value.
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Fig. 8. Arginine vasopressin (AJ/P) prior to (day 0), during (days 1 to 24),
and after (days 25 to 108) exposure to hypobaric hypoxia. Data are given as
mean SEM, N = 10.
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declined from the peak during the remaining course of the
hypoxic period, it plateaued at a significantly higher level than the
baseline value. These observations suggest that the sustained
systemic HTN in this model is not due to ANP deficiency. Earlier
studies have revealed a rise in plasma ANP in man and perfused
ventricular tissues of rats with acute hypoxia [20, 21]. The present
study confirms these observations and extends the inquiry beyond
the acute phase to long-term hypoxia and post-hypoxic phase in
this model.
Plasma AVP concentration rose insignificantly on day 1 and
returned to baseline where it remained throughout the course of
the hypoxic and post-hypoxic periods. Based on these observa-
tions, AVP does not appear to play a major role in the pathogen-
esis of the sustained systemic HTN in the present model. Inter-
estingly, acute hypoxia has been shown to increase circulating
AVP levels in fetal sheep [22]. The hypoxia-stimulated rise in
AVP is considered to play a role in ameliorating oxygen delivery
and gas exchange during fetal hypoxia [23].
Earlier studies have revealed increased circulating catechol-
amine levels in response to acute hypoxia [24—26]. The associated
hypercatecholaminemia has been shown to subside with the
restoration of normal oxygen tension in the acute setting. While
unlikely, given the long duration of hypoxia and occurrence of
systemic HTN in our animals, we wondered if catecholamines may
be elevated during the established phase of HTN in this model.
The measurements obtained several weeks following the restora-
tion of normoxia revealed normal catecholamine levels in these
hypertensive animals (data not shown). Thus, while increased
catecholamines may have, in part, contributed to the genesis of
the systemic HTN during the hypoxic phase, hypercatecholamine-
mia does not appear to be involved in the maintenance of HTN
during the post-hypoxic phase.
The rise in endothelin and catecholamine levels can potentially
contribute to the occurrence of systemic HTN during the hypoxic
phase. However, these changes generally disappear following the
restoration of normoxia. Thus, the reason for persistence of HTN
following restoration of normoxia is unclear. However, elevations
of endothelin and catecholamines along with hemodynamic stress
and other events during the extended hypoxia may have caused
structural changes to support sustained HTN beyond resolution of
the original stimulus. The notion that secondary structural remod-
eling in response to the potentially reversible primary hemody-
namic disturbances can lead to persistent HTN has been widely
implicated in the pathogenesis of certain forms of idiopathic and
acquired HTN [27, 281.
The fact that chronic hypoxia can cause systemic HTN is not
entirely surprising, since hypoxia is known to cause acute and
chronic HTN in the pulmonary circulation [29—321. Acute alveo-
lar hypoxia is known to cause pulmonary vasoconstriction leading
to acute pulmonary HTN in both human and experimental
animals. The associated pulmonary HTN and vasoconstriction are
readily reversed by restoration of normoxia. In contrast to acute
hypoxia, persistent hypoxia frequently results in chronic irrevers-
ible pulmonary HTN associated with fibrosis and vascular remod-
eling in humans and experimental animals. The latter is marked
by medial hypertrophy of the small muscular arteries and muscu-
larization of the normally nonmuscular arteries [32].
In contrast to pulmonary HTN that occurs shortly after the
onset of hypoxia, systemic blood pressure began to rise several
days after the onset of hypoxia in our animals. Therefore, systemic
HTN could have been readily missed in the course of short-term
experiments. Rapid occurrence of pulmonary HTN and delayed
occurrence of systemic HTN with hypoxia point to differences in
local factors and susceptibilities of the two vascular beds. For
instance, hypoxia has been shown to markedly raise the lung
content of substance P. a tachykinin possessing potent pulmonary
vasoconstrictive property. In fact, pretreatment with tachykinin
inhibitor, capsaicin, has been shown to mitigate hypoxia-induced
pulmonary HTN in experimental animals [33]. In addition,
chronic hypoxia appears to severely impair nitric oxide production
by pulmonary artery but not systemic arteries [34, 35]. These
observations have led to the general conclusion that chronic
hypoxia causes pulmonary but not systemic HTN. In addition to
the above studies in experimental animals, several experimental
and epidemiological studies in humans residing at high altitudes
have failed to show systemic HTN [26, 36—38]. For instance,
according to one report, individuals residing in Pikes Peak
(4300 m above sea level) for longer than two months had normal
systemic arterial blood pressure [36]. Likewise, the adapted
natives and newcomers to high altitudes have been found to be
normotensive [371 and to have normal plasma and urinary cate-
cholamine levels [26]. It should be noted, however, that large scale
longitudinal human studies are presently lacking to address the
issue with certainty.
In contrast to the above studies that suggest that chronic
hypoxia may not cause systemic HTN, rats employed in the
present study showed a steady rise in systemic blood pressure
within one to two weeks of exposure to severe chronic hypobaric
hypoxia. In fact, HTN persisted indefinitely during the post-
hypoxic period. While the preponderance of available studies
point to the primary effect of hypoxia on pulmonary but not
systemic arterial pressure, a reversible rise in systemic arterial
blood pressure has been demonstrated upon the ascent to high
altitudes in humans [25, 39—42, 44]. The latter observations along
with the findings of the present long-term animal study clearly
document that the effect of hypoxia on blood pressure is not
confined to the pulmonary circulation and can, in fact, involve the
systemic circulation as well. The clinical implication of hypoxia-
induced systemic HTN is uncertain. It is not clear if this phenom-
enon is species specific or if it is operative in the pathogenesis of
the complications of sleep apnea, a condition marked by inter-
mittent hypoxia and a high incidence of pulmonary and systemic
HTN [3—5I. Further studies are needed to elucidate the factors
involved in the pathogenesis of the sustained HTN caused by
chronic hypobaric hypoxia in this model.
In conclusion, rats exposed to chronic hypobaric hypoxia exhib-
ited severe systemic HTN that persisted long after the restoration
of normobaric condition. We have thus found a model of acquired
sustained systemic HTN in genetically normotensive rats. This
model can be employed in the studies of the pathophysiology and
treatment of systemic HTN.
Reprint requests to N. D. Vaziri, M.D., Division of Nephrology, UCI
Medical Center, 101 The City Drive, Orange, California 92668, USA.
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